Miniatura

Fitxers

904913.pdf (1.73 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-05-05

Llicència de publicació

cc-by (c) Oñate, G. et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/224473

Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3mut). We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098). Patients were divided into an early (2012-2015) and late (2016-2020) cohorts. They were uniformly treated except for the addition of midostaurin in 71% of late group patients. No differences were observed in response rates or the number of allotransplants between groups. Outcome was improved in the late period: 2-year relapse incidence decreased from 42% vs 29% in early vs late group (p = 0.024) and 2-year overall survival (OS) improved from 47% vs 61% (p = 0.042), respectively. The effect of midostaurin was evident in NPM1mut patients (n = 151), with 2-yr OS of 72% (exposed) vs 50% (naive) patients (p = 0.011) and mitigated FLT3-ITD allelic ratio prognostic value: 2-yr OS with midostaurin was 85% and 58% in low and high ratio patients (p = 0.049) vs 67% and 39% in naive patients (p = 0.005). In the wild-type NPM1 subset (n = 75), we did not observe significant differences between both study periods. In conclusion, this study highlights the improved outcome of FLT3mut AML fit patients with the incorporation of midostaurin.

Descripció

Matèries

Pronòstic mèdic, Leucèmia mieloide, Mutació (Biologia)

Matèries (anglès)

Prognosis, Myeloid leukemia, Mutation (Biology)

Citació

Col·leccions

Articles publicats en revistes (Infermeria Fonamental i Clínica)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SAMPOL, Antonia, GARCIA, Antoni, CERVERA, Marta, GARCIA AVILA, Sara, BARGAY, Joan, ORTÍN, Xavier, NOMDEDÉU GUINOT, Josep francesc, ESTEVE, Jordi, SIERRA GIL, Jorge, OÑATE, Guadalupe, PRATCORONA, Marta, GARRIDO, Ana, ARTIGAS-BALERI, Alicia, BATALLER TORRALBA, Alex, TORMO, Mar, ARNAN, Montserrat, VIVES, Susana, COLL, Rosa, SALAMERO, Olga, VALL LLOVERA, Ferran. Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. _Blood Cancer Journal_. 2023. Vol. 13, núm. 1. [consulta: 6 de desembre de 2025]. ISSN: 2044-5385. [Disponible a: https://hdl.handle.net/2445/224473]

Exportar metadades

JSON - METS

Compartir registre